top of page

The EU and pharmaceutical companies offer € 130 million in support to researchers and developers

Until 24 October 2017, research institutes and small and medium-sized enterprises can apply for the twelfth call of the IMI 2 initiative. This is a public partnership project supported by the EU and major pharmaceutical companies. Support usually goes to areas where progress is really urgent. Currently, for example, this is research into Alzheimer's disease. Aid worth € 130 million is now available in IMI 2, but Czech entities can only apply for part of these resources.

One of the selected topics is the vaccination of the elderly. They gradually weaken their immune systems and are therefore particularly vulnerable to infectious diseases. The aim of IMI 2 participants is to study the burden of infectious diseases in people over the age of 50, to develop and simulate programs to reduce the burden of these diseases, or to study the immune response to vaccination in people over the age of 65. The ultimate goal is to design a vaccination program for the elderly comparable to the existing vaccination program for children.

You can read the whole article here.

2 views0 comments

Recent Posts

See All

A promising company emerged from the student project

Another successful project at the Institute of Organic Chemistry and Biochemistry of the ASCR is in the world. Originally a student project, a new company DIANA Biotechnologies was created at this ins

Scientists are interested in how to live 120 years

The ENOCH consortium, whose members are five Moravian biomedical institutions, is to bring knowledge for six years to combat diseases that are often associated with an aging population. "Research will


bottom of page